James Empfield

James Empfield appears in our data through filings on Xenon Pharmaceuticals Inc. shares, published by SEC (Form 4). In total, 7 filings cover trades dated from 8 February 2016 to 12 August 2022.

Market trades split into 1 purchase (€17k) and 2 sales (€1.7M). Taken together, the sales exceed the purchases by €1.7M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 option exercises. Since January 2022: no purchases and 2 sales on the market.

The latest filing, published on 16 August 2022, reports an open-market sale of €642k in Xenon Pharmaceuticals Inc. The last insider purchase was made public on 17 August 2017, 3,372 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.